Urogen Pharma Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
291
- Stock Symbol
-
URGN
- Investments
-
3
- Share Price
-
$26.20
- (As of Friday Closing)
Urogen Pharma General Information
Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Contact Information
Website
www.urogen.comCorporate Office
- 400 Alexander Park Drive
- 4th Floor
- Princeton, NJ 08540
- United States
Corporate Office
- 400 Alexander Park Drive
- 4th Floor
- Princeton, NJ 08540
- United States
Urogen Pharma Timeline
Urogen Pharma Stock Performance
As of 13-Nov-2026, Urogen Pharma’s stock price is $26.20. Its current market cap is $1.28B with 49M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $26.20 | $26.39 | $16.50 - $50.81 | $1.28B | 49M | 1.01M | -$1.32 |
Urogen Pharma Financials Summary
As of 30-Sep-2026, Urogen Pharma has a trailing 12-month revenue of $250M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,074,170 | 1,097,583 | 321,770 | 415,120 |
| Revenue | 250,253 | 109,788 | 90,398 | 82,713 |
| EBITDA | (47,246) | (141,625) | (119,236) | (84,545) |
| Net Income | (65,751) | (153,494) | (126,874) | (102,244) |
| Total Assets | 271,873 | 200,455 | 285,711 | 178,311 |
| Total Debt | 196,283 | 128,332 | 123,387 | 99,395 |
Urogen Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Urogen Pharma Comparisons
Industry
Financing
Details
Urogen Pharma Competitors (14)
One of Urogen Pharma’s 14 competitors is Rapid Dose Therapeutics, a Corporation company based in Burlington, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rapid Dose Therapeutics | Corporation | Burlington, Canada | ||||
| Heron Therapeutics | Formerly VC-backed | Cary, NC | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA |
Urogen Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Urogen Pharma Patents
Urogen Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026033517-A1 | Device for introducing liquids into the urinary tract | Pending | 05-Aug-2024 | ||
| AU-2024301406-A1 | Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin | Pending | 25-Jul-2023 | ||
| EP-4750468-A1 | Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin | Pending | 25-Jul-2023 | ||
| WO-2025022354-A1 | Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin | Inactive | 25-Jul-2023 | ||
| US-12740940-B2 | Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin | Active | 25-Jul-2023 | A61K9/06 |
Urogen Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Urogen Pharma Investments & Acquisitions (3)
Urogen Pharma’s most recent deal was a Early Stage VC with Intragel Therapeutics for . The deal was made on 20-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Intragel Therapeutics | 20-Aug-2026 | Early Stage VC | Drug Delivery | ||
| IconOVir (Portfolio of Oncolytic Virus Assets in United States) | 14-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Telormedix | 01-Jan-2015 | Merger/Acquisition | Pharmaceuticals |
Urogen Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.86 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Urogen Pharma FAQs
-
When was Urogen Pharma founded?
Urogen Pharma was founded in 2004.
-
Where is Urogen Pharma headquartered?
Urogen Pharma is headquartered in Princeton, NJ.
-
What is the size of Urogen Pharma?
Urogen Pharma has 291 total employees.
-
What industry is Urogen Pharma in?
Urogen Pharma’s primary industry is Drug Delivery.
-
Is Urogen Pharma a private or public company?
Urogen Pharma is a Public company.
-
What is Urogen Pharma’s stock symbol?
The ticker symbol for Urogen Pharma is URGN.
-
What is the current stock price of Urogen Pharma?
As of 13-Nov-2026 the stock price of Urogen Pharma is $26.20.
-
What is the current market cap of Urogen Pharma?
The current market capitalization of Urogen Pharma is $1.28B.
-
What is Urogen Pharma’s current revenue?
The trailing twelve month revenue for Urogen Pharma is $250M.
-
Who are Urogen Pharma’s competitors?
Rapid Dose Therapeutics, Heron Therapeutics, Nurix Therapeutics, Cullgen, and ImmunityBio are some of the 14 competitors of Urogen Pharma.
-
What is Urogen Pharma’s annual earnings per share (EPS)?
Urogen Pharma’s EPS for 12 months was -$1.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
